Indeed, when we carried out in vitro experiments, we found that features of immune activation that are observed after HIV infection of APC could most significantly be impacted by treatment with a p38 MAPK inhibitor but also by a JNK inhibitor and to a lesser extent by an ERK inhibitor [45–47]. This evidence concerns the gene MAPK8 and HIV infectious disease.